Nissar Darmani, PhD
Associate Dean for Basic Sciences
and Research; Chair of BMS;
Professor of Pharmacology
College of Osteopathic Medicine of the Pacific
Join year: 2005
Ph.D., Neuropharmacology, University of Wales, UWIST, U.K., 1988
M.S., Applied Pharmacology, University of Wales, UWIST, U.K., 1984
Medical Scientific Officer, Immunohematology Center, Cambridge, UK, 1979-1983
B.S., Honors: Pharmacology & Biochemistry, Leeds University, England, U.K., 1979
Postdoctoral Fellow, Neuropsychopharmacology, Department of Pharmacology, Medical College of Virginia, 1988-1991
Associate Dean of BMS and Research, Western University of Health Sciences, COMP, 2011-present
Assistant Dean of BMS and Research, Western University of Health Sciences, COMP, 2008-2011
Chair, Department of Basic Medical Sciences, Western University of Health Sciences, COMP 2005-present
Professor, Department of Pharmacology, Kirksville College of Osteopathic Medicine, Kirksville, MO, 2000-2005
Associate Professor, Department of Pharmacology, Kirksville College of Osteopathic Medicine, Kirksville, MO, 1995-2000
Assistant Professor, Department of Pharmacology, Kirksville College of Osteopathic Medicine, Kirksville, MO, 1991-1995
Research Assistant Professor, Department of Pharmacology, Medical College of Virginia, 1991
Dr. Darmani's main training has been in the field of pharmacology and will be teaching the core pharmacology course involving introduction to pharmacology, pharmacodynamics and pharmacokinetics.
Dr. Darmani has several avenues of research interest that include:
- Developmental effects of drugs of abuse on the newborn.
- Serotonergic mechanisms of cocaine's actions.
- Mode of action of antidepressant drugs.
- Adaptive mechanisms of serotonergic 5-HT2 receptor functions.
- The role of delta-9 -THC and synthetic cannabinoids on chemotherapy- and radiotherapy-induced vomiting. His laboratory had the first opportunity to demonstrate the mechanisms of antiemetic actions of marijuana.
- Role of 5-HT3-, Dopamine D2/3-, Lekotriene CysLT1- and NK1- receptors in emesis and application of their antagonists as antiemetics.
- Another of his research interests involves the role of osteopathic manipulative medicine on the blood levels of endogenous cannabinoid-like compounds and other pain markers in patients with back pain. He had been successful in obtaining several million dollars of research grants from numerous funding agencies including the Pharmaceutical industry, the National Institute of Drug Abuse, the National Institute of Cancer, the Department of Defense and the Environmental Protection Agency.
- Zhong, W.; Picca, A.J.; Lee, A.S.; Darmani, N.A. (2016) Ca2+ signaling and emesis: Recent progress and new perspectives. Auton Neurosci. 202:18-27. July 2016
- Zhong, W.; Chebolu, S.; Darmani, N. (2016) Thapsigargin-induced activation of Ca2+- CaMKII-ERK in brainstem contributes to substance P release and induction of emesis in the least shrew. Neuropharmacology. 2016 Apr;103:195-210. doi:10.1016/j.neurpopharm.2015.11.023. Epub 2015 Nov 26.
- Darmani, N.A., Zhong, W.; Chebolu, S.; Mercardante, F. (2015) Differential and additive suppressive effects of the 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation. Pharmocol.Biochem. Behav. 131:104-111.
- Hutchison, T.E.; Zhong, W.; Chebolu, S.; Wilson, S.M.; Darmani, N.A. (2015) L-type calcium channels contribute to 5-HT3-receptor-evoked CaMKIIa and ERK activation and induction of emesis in the least shrew (Cryptotis parva). Eur. J. Pharmacol. 755:110-118.
- Zhong W, Hutchinson TE, Chebolu S, Darmani NA. (2014) Serotonin 5-HT3 receptor-mediated vomiting occurs via the activation of Ca2+/CaMKII-dependent ERK1/2 signaling in the least shrew (Cryptotis parva). PLoS One. 2014 Aug 14;9(8):e104718. doi: 10.1371/journal.pone.0104718. eCollection 2014.
- Zhong W, Chebolu S, Darmani NA. (2014) Broad-spectrum antiemetic efficacy of the L-type calcium channel blocker amlodipine in the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 2014 May;120:124-32. doi: 10.1016/j.pbb.2014.03.005.
- Darmani NA, Zhong W, Chebolu S, Vaezi M, Alkam T. (2014) Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva). Eur J Pharmacol. 2014 Jan 5;722:2-12.
- Alkam T, Chebolu S, Darmani NA. (2014) Cyclophosphamide causes activation of protein kinase A (PKA) in the brainstem of vomiting least shrews (Cryptotis parva). Eur J Pharmacol. 2014 Jan 5;722:156-64.
- Darmani NA. (2014) Preface. New vistas in the pharmacology and neurochemistry of diverse causes of nausea and vomiting. Eur J Pharmacol. 2014 Jan 5;722:1. doi: 10.1016/j.ejphar.2013.12.012. No abstract available.
- Sharkey KA, Darmani NA, Parker LA. (2014) Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014 Jan 5;722:134-46. doi: 10.1016/j.ejphar.2013.09.068. Epub 2013 Nov 1.
- Darmani NA, Chebolu S, Zhong W, Trinh C, McClanahan B, Brar RS. (2014) Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva). Eur J Pharmacol. 2014 Jan 5;722:147-55. doi: 10.1016/j.ejphar.2013.08.051. Epub 2013 Oct 22.
- Darmani NA, Chebolu S. (2013) The role of endocannabinoids and arachidonic acid metabolites in emesis. In: Endocannabinoids: Molecular, pharmacological, behavioral and clinical features:(Murillo-Rodriguez, E.; Onaive, E.S.; Darmani, N.A. and Wagner,E. eds. Bentham e Books, Chapter 2, pp 25-59.
- Darmani NA. (2013) New vistas in the pathophysiology of vomiting. Family Medicine Medical Science Res. 2:1. http//dx.doi.org/10.4172/fmmer.1000e105.
- Darmani NA, Dey D, Chebolu S, Amos B, Kandpal R. (2013) Cisplatin causes over-expression of neurokinin NK1 receptors and increases ERK1/2- and PKA-phosphorylation during peak immediate- and delayed-phase emesis in the least shrew (Cryptotis parva) brainstem. Eur. J. Pharmacol. 698: 161-169.
- Al-Tikriti MS, Khamas W, Chebolu S, Darmani NA. (2012) Distribition of serotonin-immunoreactive chromaffin cells in the gastrointestinal tract of the least shrew (Cryptotis parva). Int. J. Morphology 30: 916-923.
Darmani NA, Chebolu S, Amos B, Alkam T. (2011) Synergistic interactions between serotonergic 5-HT(3) and tachykininergic NK(1)-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 99: 573-579.
Click links below for additional publications and information: